The asthma and peanut allergy treatment company has now raised $89m in total, after closing a series D round backed by BioMed Realty and returning investor Novo.
US-based biotechnology company AnaptysBio closed an oversubscribed $40m series D round yesterday that included pharmaceutical company Novo and biotechnology real estate company BioMed Realty’s corporate venturing arm, BioMed Ventures.
BVF Partners, Cormorant Asset Management, Frazier Healthcare, HBM Healthcare Investments and Longwood Capital Partners, as well as a range of undisclosed backers, also took part in the round.
Founded in 2005, AnaptysBio is developing therapeutic antibodies to treat severe adult asthma and peanut allergies, as well as generalised pustular psoriasis –…
